List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6632870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Source of Chronic Inflammation in Aging. Frontiers in Cardiovascular Medicine, 2018, 5, 12.	2.4	267
2	Therapeutic Angiogenesis Induced by Human Recombinant Hepatocyte Growth Factor in Rabbit Hind Limb Ischemia Model as Cytokine Supplement Therapy. Hypertension, 1999, 33, 1379-1384.	2.7	262
3	Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease. Hypertension, 2004, 44, 203-209.	2.7	208
4	Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model. Circulation, 2001, 104, 2344-2350.	1.6	184
5	Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. Circulation, 2000, 102, 246-252.	1.6	182
6	Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Frontiers in Aging Neuroscience, 2014, 6, 171.	3.4	173
7	Mitogenic and Antiapoptotic Actions of Hepatocyte Growth Factor Through ERK, STAT3, and Akt in Endothelial Cells. Hypertension, 2001, 37, 581-586.	2.7	146
8	The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Frontiers in Aging Neuroscience, 2015, 7, 199.	3.4	134
9	A Vascular Modulator, Hepatocyte Growth Factor, Is Associated With Systolic Pressure. Hypertension, 1996, 28, 409-413.	2.7	113
10	Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF). Current Gene Therapy, 2004, 4, 199-206.	2.0	110
11	Ribozyme Oligonucleotides Against Transforming Growth Factor-Î ² Inhibited Neointimal Formation After Vascular Injury in Rat Model. Circulation, 2000, 102, 1308-1314.	1.6	97
12	OPC/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8191-8196.	7.1	93
13	Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature Aging, 2021, 1, 1117-1126.	11.6	87
14	Molecular therapy to inhibit NFκB activation by transcription factor decoy oligonucleotides. Current Opinion in Pharmacology, 2004, 4, 139-146.	3.5	85
15	Novel Method for Rapid Assessment of Cognitive Impairment Using High-Performance Eye-Tracking Technology. Scientific Reports, 2019, 9, 12932.	3.3	73
16	Contribution of Bcl-2, but Not Bcl-xL and Bax, to Antiapoptotic Actions of Hepatocyte Growth Factor in Hypoxia-Conditioned Human Endothelial Cells. Hypertension, 2001, 37, 1341-1348.	2.7	72
17	Regression of Abdominal Aortic Aneurysms by Simultaneous Inhibition of Nuclear Factor κB and Ets in a Rabbit Model. Circulation Research, 2007, 101, 1175-1184.	4.5	66
18	The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nature Communications, 2020, 11, 2482.	12.8	64

#	Article	IF	CITATIONS
19	Hepatocyte Growth Factor as Cardiovascular Hormone: Role of HGF in the Pathogenesis of Cardiovascular Disease. Endocrine Journal, 2002, 49, 273-284.	1.6	61
20	Selective Blockade of Periostin Exon 17 Preserves Cardiac Performance in Acute Myocardial Infarction. Hypertension, 2016, 67, 356-361.	2.7	56
21	Brain Alterations and Clinical Symptoms of Dementia in Diabetes: Aβ/Tau-Dependent and Independent Mechanisms. Frontiers in Endocrinology, 2014, 5, 143.	3.5	52
22	Role of Transcriptional cis -Elements, Angiotensinogen Gene–Activating Elements, of Angiotensinogen Gene in Blood Pressure Regulation. Hypertension, 1996, 27, 502-507.	2.7	48
23	Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. International Journal of Molecular Medicine, 2008, 22, 703-8.	4.0	46
24	A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis. Atherosclerosis Supplements, 2005, 6, 41-46.	1.2	44
25	Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice. PLoS ONE, 2013, 8, e60493.	2.5	44
26	Possible modification of Alzheimerââ,¬â"¢s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Frontiers in Aging Neuroscience, 2014, 6, 71.	3.4	43
27	Inhibition of Growth of Human Vascular Smooth Muscle Cells by Overexpression of p21 Gene Through Induction of Apoptosis. Hypertension, 1998, 31, 493-498.	2.7	42
28	Current therapies and investigational drugs for peripheral arterial disease. Hypertension Research, 2016, 39, 183-191.	2.7	40
29	Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1256-63.	7.1	39
30	Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model. Hypertension, 2001, 37, 270-274.	2.7	37
31	Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. Hypertension, 2015, 66, 167-174.	2.7	37
32	Low alpha-synuclein levels in the blood are associated with insulin resistance. Scientific Reports, 2015, 5, 12081.	3.3	36
33	Transfection of Antisense <i>p53</i> Tumor Suppressor Gene Oligodeoxynucleotides Into Rat Carotid Artery Results in Abnormal Growth of Vascular Smooth Muscle Cells. Circulation, 2000, 101, 1447-1452.	1.6	35
34	Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy, 2015, 16, 417-426.	1.8	35
35	Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. Hypertension, 2018, 72, 1355-1364.	2.7	35
36	Perspective in Progress of Cardiovascular Gene Therapy. Journal of Pharmacological Sciences, 2004, 95, 1-8.	2.5	34

#	Article	IF	CITATIONS
37	The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertension Research, 2014, 37, 629-635.	2.7	34
38	Initial Clinical Cases of the Use of a NFKAPPA.B Decoy at the Site of Coronary Stenting for the Prevention of Restenosis. Circulation Journal, 2004, 68, 270-271.	1.6	33
39	Systemic Administration of Ribbon-type Decoy Oligodeoxynucleotide Against Nuclear Factor κB and Ets Prevents Abdominal Aortic Aneurysm in Rat Model. Molecular Therapy, 2011, 19, 181-187.	8.2	33
40	Roles of vascular risk factors in the pathogenesis of dementia. Hypertension Research, 2020, 43, 162-167.	2.7	33
41	Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. Hypertension Research, 2014, 37, 500-506.	2.7	32
42	Recent Progress in Gene Therapy for Cardiovascular Disease Circulation Journal, 2002, 66, 1077-1086.	1.6	29
43	Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. Stroke, 2017, 48, 1362-1368.	2.0	29
44	A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke. Scientific Reports, 2016, 6, 38062.	3.3	28
45	A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific Reports, 2017, 7, 43920.	3.3	25
46	The Biphasic Effects of Oxidized-Low Density Lipoprotein on the Vasculogenic Function of Endothelial Progenitor Cells. PLoS ONE, 2015, 10, e0123971.	2.5	22
47	Angiotensinogen Gene–Activating Elements Regulate Blood Pressure in the Brain. Circulation Research, 1999, 85, 257-263.	4.5	20
48	Recent Advances in Therapeutic Vaccines to Treat Hypertension. Hypertension, 2018, 72, 1031-1036.	2.7	20
49	Effect of angiotensin <scp>II</scp> receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. Geriatrics and Gerontology International, 2015, 15, 1064-1072.	1.5	19
50	Therapeutic effect of intraâ€articular injection of ribbonâ€ŧype decoy oligonucleotides for hypoxia inducible factorâ€1 on joint contracture in an immobilized knee animal model. Journal of Gene Medicine, 2016, 18, 180-192.	2.8	18
51	Different roles played by periostin splice variants in retinal neovascularization. Experimental Eye Research, 2016, 153, 133-140.	2.6	18
52	Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Review of Cardiovascular Therapy, 2014, 12, 1145-1156.	1.5	17
53	Prevention of Asthma Exacerbation in a Mouse Model by Simultaneous Inhibition of NF-ήB and STAT6 Activation Using a Chimeric Decoy Strategy. Molecular Therapy - Nucleic Acids, 2018, 10, 159-169.	5.1	17
54	Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke. Scientific Reports, 2018, 8, 17770.	3.3	16

#	Article	IF	CITATIONS
55	Progress of Gene Therapy in Cardiovascular Disease. Hypertension, 2020, 76, 1038-1044.	2.7	16
56	Long-term expression of periostin during the chronic stage of ischemic stroke in mice. Hypertension Research, 2014, 37, 494-499.	2.7	15
57	Increased levels of Aβ42 decrease the lifespan of ob/ob mice with dysregulation of microglia and astrocytes. FASEB Journal, 2020, 34, 2425-2435.	0.5	15
58	Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. Current Gene Therapy, 2020, 20, 25-35.	2.0	14
59	Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model. Circulation: Cardiovascular Interventions, 2014, 7, 787-796.	3.9	13
60	Dysfunctional high density lipoprotein failed to rescue the function of oxidized low density lipoprotein-treated endothelial progenitor cells: a novel index for the prediction of HDL functionality. Translational Research, 2019, 205, 17-32.	5.0	13
61	HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque. Current Drug Targets, 2002, 3, 379-385.	2.1	13
62	Does gene therapy become pharmacotherapy?. Experimental Physiology, 2005, 90, 307-313.	2.0	12
63	Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse. Hypertension Research, 2015, 38, 382-393.	2.7	12
64	Inhibition of Aneurysm Progression by Direct Renin Inhibition in a Rabbit Model. Hypertension, 2017, 70, 1201-1209.	2.7	12
65	Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis. Scientific Reports, 2019, 9, 15434.	3.3	10
66	Modeling transient retinal ischemia in mouse by ligation of pterygopalatine artery. Annals of Neurosciences, 2015, 22, 222-5.	1.7	10
67	Adventure of Gene Therapy Into the Brain: A New Era for Cardiovascular Gene Therapy. Circulation Research, 2000, 87, 719-721.	4.5	9
68	Therapeutic Potential of Oligonucleotide-Based Therapy in Cardiovascular Disease. BioDrugs, 2003, 17, 383-389.	4.6	9
69	Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice. Current Hypertension Reports, 2018, 20, 22.	3.5	9
70	Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm. Annals of Vascular Diseases, 2019, 12, 137-146.	0.5	9
71	Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. BioMed Research International, 2018, 2018, 1-8.	1.9	8
72	Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. Hypertension Research, 2022, 45, 61-65.	2.7	8

#	Article	IF	CITATIONS
73	Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model. Hypertension, 2020, 76, 1879-1888.	2.7	7
74	Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research, 2021, 44, 1047-1053.	2.7	7
75	Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines, 2014, 2, 832-840.	4.4	6
76	Transplantation of lineage-negative stem cells in pterygopalatine artery ligation induced retinal ischemia–reperfusion injury in mice. Molecular and Cellular Biochemistry, 2017, 429, 123-136.	3.1	6
77	Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study. Current Vascular Pharmacology, 2012, 10, 178-186.	1.7	5
78	Links Between Hypertension and Osteoporosis: Benidipine Ameliorates Osteoporosis in Ovariectomized Hypertensive Rats Through Promotion of Osteoblast Proliferation and Inhibition of Osteoclast Differentiation. Current Cardiovascular Risk Reports, 2012, 6, 274-280.	2.0	5
79	Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice. ImmunoHorizons, 2021, 5, 438-447.	1.8	5
80	Future Directions of Therapeutic Vaccines for Chronic Diseases. Circulation Journal, 2020, 84, 1895-1902.	1.6	5
81	Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey. Scientific Reports, 2021, 11, 11472.	3.3	4
82	Prevention of vascular dementia via immunotherapeutic blockade of renin-angiotensin system in a rat model. Brain Research, 2021, 1772, 147667.	2.2	4
83	A novel chronic dural port platform for continuous collection of cerebrospinal fluid and intrathecal drug delivery in free-moving mice. Fluids and Barriers of the CNS, 2022, 19, 31.	5.0	4
84	Influence of periostin-positive cell-specific Klf5 deletion on aortic thickening in DOCA-salt hypertensive mice. Hypertension Research, 2016, 39, 764-768.	2.7	3
85	Development of Oral Formulation Technology for Nucleic Acid Drug by Using PLGA Nanoparticles as DDS Carriers. Journal of the Society of Powder Technology, Japan, 2013, 50, 513-518.	0.1	3
86	[36] HVJ (hemagglutinating virus of Japan; Sendai virus)-liposome method. Methods in Enzymology, 2002, 346, 619-627.	1.0	2
87	Angiogenesis and Its Therapeutic Implication 4. Cardiovascular Disease and Angiogenesis. Internal Medicine, 2003, 42, 301-302.	0.7	1
88	Eight-Year Follow-Up of an Initial Case with NF-?B Decoy Oligodeoxynucleotide Transfection After Coronary Stent Implantation. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 40-42.	0.5	1
89	New era in gene therapy: end of the beginning. Expert Opinion on Biological Therapy, 2015, 15, 309-310.	3.1	1
90	Angiotensin Receptor Blocker Protects Alzheimer's Disease Brain From Ischemic Insult. American Journal of Hypertension, 2017, 30, 110-111.	2.0	1

#	Article	IF	CITATIONS
91	Preface: Transcription Factor as Molecular Targets: Is Transcription Factor Decoy a Novel Drug ? [Hot topic: Transcription Factor as Molecular Targets (Guest Editor: Ryuichi Morishita)]. Current Drug Targets, 2003, 4, i-i.	2.1	0
92	Polymorphism of myospryn is associated with left ventricular diastolic dysfunction. Anti-aging Medicine, 2008, 5, 49-52.	0.7	0
93	How to evaluate real-world medicine in a Japanese population: important lessons from the JIKEI, CASE-J, KYOTO and VART studies. Hypertension Research, 2011, 34, 33-35.	2.7	0
94	Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults. Translational and Regulatory Sciences, 2021, , .	0.2	0
95	Gene therapy for neurological diseases(Plenary Session 3 Application of gene diagnosis and gene) Tj ETQq1 1 0.7	'84314 rgl 0.0	3T /Overloc <mark>k</mark>
96	INHIBITION OF NEOINTIMAL FORMATION AND INCREASED LOCAL VASCULAR HEPATOCYTE GROWTH FACTOR (HGF) PRODUCTION IN BALLOON INJUREDARTERIFSBY ANGIOTENSIN CONVERTING ENZYME INHIBITOR. International Heart Journal, 1997, 38, 577-577.	0.6	0
97	Present and Future in the genetherapy for cardiovascnlardisease. The Journal of Japan Atherosclerosis Society, 1999, 26, 263-268.	0.0	0
98	Ultrasound attacks Alzheimer's disease?. Annals of Translational Medicine, 2015, 3, 276.	1.7	0